Harmony Biosciences Holdings Inc. Common Stock (HRMY)

FairStock Score: 73/100 — STEADY

Key Financials

Strengths

• Generates $211 million in annual free cash flow (11.5% yield on market cap)
• High return on equity of 20.8% demonstrating efficient capital deployment
• Conservative balance sheet with debt-to-equity of just 0.19, providing financial flexibility
• Revenue growth of 21.1% demonstrates strong top-line momentum
• FairStock composite score of 73/100 places it in the top tier across value, quality, and momentum factors

AI Analysis

Harmony Biosciences Holdings Inc. Common Stock is a micro-cap healthcare company valued at $1.8 billion. The business generates $868 million in annual revenue with a 2.6% net margin and $211 million in free cash flow. From a quality standpoint, Harmony shows healthy Altman Z-Score of 3.8 and strong 21% ROE. On valuation, the stock is attractively valued at 11.8x earnings, with trades above its Graham Number with a negative 5% margin. Growth dynamics show revenue growing at 21.1% and profit growth of -54.5%. Our composite FairStock Score of 73/100 reflects above-average fundamentals overall. This combination of reasonable valuation, solid returns, and conservative leverage makes it worth a closer look for value-oriented portfolios.

Bull Case

Harmony's 21% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. With $211 million in annual free cash flow (11.5% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer